Johnson & Johnson’s Janssen R&D LLC announced the launch of three new research platforms Feb. 12 with the goal of uncovering transformational innovation targeted at preventing disease or treating early disease. The three new areas are focused on understanding the very earliest stages of disease and emerging fields of research, the company said.
Janssen R&D is centering the new platforms around areas it calls disease prevention, disease interception and the microbiome. The announcement...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?